Gilead Sciences (GILD) Cash & Current Investments (2009 - 2026)

Gilead Sciences (GILD) has reported Cash & Current Investments for 18 consecutive years, with $7.6 billion the latest figure, recorded in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $7.6 billion, down 3.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.6 billion (down 3.57% YoY), and the FY2025 annual result was $7.6 billion, down 23.61% from the prior year.
• Cash & Current Investments was $7.6 billion for Q1 2026 at Gilead Sciences, roughly flat from $7.6 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $10.0 billion in Q4 2024 and troughed at $2.8 billion in Q2 2024.
• Average Cash & Current Investments over 5 years is $6.4 billion, with a median of $6.4 billion recorded in 2022.
• Year-over-year, Cash & Current Investments sank 58.42% in 2024 and jumped 88.06% in 2025.
• Over 5 years, Cash & Current Investments stood at $6.4 billion in 2022, then increased by 13.77% to $7.3 billion in 2023, then soared by 37.54% to $10.0 billion in 2024, then declined by 23.61% to $7.6 billion in 2025, then rose by 0.14% to $7.6 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $7.6 billion in Q1 2026, $7.6 billion in Q4 2025, and $7.3 billion in Q3 2025.